NCT06955104

Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 145 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

Detailed description

To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	JW0108 + C2407	JW0108 + C2407
DRUG	JW0108 + C2407 placebo	JW0108 + C2407 placebo

Timeline

• Start date: 2025-04-03
• Primary completion: 2025-07-30
• Completion: 2025-07-30
• First posted: 2025-05-02
• Last updated: 2025-09-03

Locations

1 site across 1 country: South Korea